socalTECH

MAY 16, 2011

Pasadena-based venture capital firm Arcturus Capital has scored an exit out of its portfolio this morning, as Milpitas, California-based Pliant Technology was acquired by SanDisk in a deal worth $327M. SanDisk said it would pay $327M in cash, plus equity-based incentives for Pliant, a developer of enterprise solid state disk drives (SSDs).

Arcturus 150

Arcturus Pasadena Venture Capital Equity 150

Xconomy

OCTOBER 23, 2017

Things have been moving quickly in recent weeks for the San Diego RNA drug developer Arcturus Therapeutics. After initiating a reverse merger last month, Arcturus signed a research collaboration and worldwide licensing agreement with Janssen Pharmaceuticals, part of the Johnson & Johnson (NYSE: JNJ ) family of companies.

Arcturus 65

Arcturus San Diego Research Develop 65

Xconomy

FEBRUARY 2, 2018

Arcturus Therapeutics (NASDAQ: ARCT ) said today it has fired co-founder and CEO Joseph E. Payne (on the right in above photo), and named Mark Herber, vice president of business development and alliance management, as interim president. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Arcturus 56

Arcturus San Diego Pricing Report 56

Xconomy

MAY 30, 2018

The San Diego RNA drug developer Arcturus Therapeutics (NASDAQ: ARCT ) named four new board members Tuesday, after the four directors who fired founding CEO Joseph Payne resigned as part of a settlement agreement that was approved Monday by an Israeli court. No financial terms were disclosed.

Arcturus 56

Arcturus San Diego Develop Development 56

Xconomy

MAY 30, 2017

San Diego-based Arcturus Therapeutics said today Cystic Fibrosis Foundation Therapeutics has agreed to provide $3 million to fund research and development of a new messenger RNA drug that could be broadly used to treat cystic fibrosis patients. Arcturus says its technology can be used to make.

Arcturus 65

Arcturus San Diego Research Funding 65

Xconomy

FEBRUARY 27, 2018

The schism between Arcturus Therapeutics’ board and its former chief executive is now putting the company at risk of missing key financial reporting deadlines, and possibly even losing its stock listing. The San Diego drug developer said late Monday that the typically routine step of ratifying the company’s auditor failed a shareholder vote.

Arcturus 49

Arcturus San Diego Report Develop 49

Xconomy

MAY 31, 2018

The San Diego RNA drug developer Arcturus Therapeutics (NASDAQ: ARCT ) on Thursday reinstated fired CEO Joseph Payne and named ResMed (NYSE: RMD ) founder Peter Farrell as chairman of the company’s new board of directors. He co-founded Arcturus and is the company’s largest shareholder, with a 13.7 percent stake.

Arcturus 49

Arcturus San Diego Develop Development 49

Xconomy

MARCH 29, 2018

The board that fired Arcturus Therapeutics co-founder and CEO Joseph E. Payne earlier this year unleashed a new broadside this week in the ongoing battle for control of the San Diego-based RNA drug developer. Payne, who. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Arcturus 49

Arcturus San Diego Develop Development 49

socalTECH

JUNE 15, 2010

Monrovia, California-based Prolacta Bioscience , the venture backed firm developing human milk fortifiers for premature infants, announced this morning that it will be donating funds to the Susan G. Komen for the Cure as part of its milk donation program.

Arcturus 221

Arcturus Draper Monrovia Funding 221

socalTECH

SEPTEMBER 23, 2011

Prolacta has been developing processes which process human milk, and convert that into human milk fortifier which helps prevent medical issues often encountered by feeding premature babies with cow-based fortifiers. According to Prolacta, the National Milk Bank will recruit potential breast milk donors for Prolacta. READ MORE>>.

Arcturus 166

Arcturus Draper Monrovia Capital 166

socalTECH

FEBRUARY 25, 2009

Most recently, XIFIN said, Zaniboni was CFO of AviaraDx, while Taylor served as vice president of marketing and corporate development for Acclerys Inc. Zaniboni was also CFO for Arcturus Bioscience and Sequenom, XIFIN noted, adding that Taylor worked at IBM as a strategy executive prior to Acclerys.

Arcturus 100

Arcturus Marketing IBM IBM 100

socalTECH

JANUARY 22, 2009

Santa Monica-based Zag , which has developed an automobile configuration and buying service for affinity organizations like credit unions and automobile organizations, has a funding round of undisclosed size. The spokesperson for Zag said that the firm is "not quite ready to make that announcement" and would not releas details until later.

Zag 100

Zag Funding Tech Coast Angels Arcturus 100

socalTECH

JANUARY 22, 2009

Santa Monica-based Zag , which has developed an automobile configuration and buying service for affinity organizations like credit unions and automobile organizations, has raised around $32.4M in a funding round. A spokesperson for Zag told socalTECH that a round had closed, but would not confirm the investors or details of the round.

Zag 100

Zag Tech Coast Angels Arcturus GRP Partners 100

socalTECH

OCTOBER 24, 2008

Long Beach-based Digital Performance, which develops technology for online sales efforts in the after market automotive parts sector, is announcing Monday that it has raised $3.2M The round was led by Rincon Venture Partners, and also included Arcturus Capital and Momentum Venture Management. in a Series A funding round.

Arcturus 100

Arcturus Long Beach Resource Capital 100

socalTECH

OCTOBER 14, 2008

Santa Monica-based Zag, a venture-backed developer of online car buying software, said this morning that it has made. Zag said it has promoted Bernie Brenner to Executive Vice President in charge of the firm's consumer initiatives, named David Pributsky as VP of Partner development. a number of hires and a promotion. READ MORE>>

Zag 100

Zag Arcturus GRP Partners Anthem 100

socalTECH

OCTOBER 6, 2008

Santa Monica-based Zag, which is developing software for auto buying programs, has signed on another AAA group as a customer. Zag has developed a software product which allows users to fully configure and price cars for car buying programs and affinity groups; the firm's software is already being used by a number of other AAA clubs.

Zag 100

Zag CarsDirect Arcturus GRP Partners 100

socalTECH

OCTOBER 21, 2013

San Diego-based Arcturus Therapeutics , a developer of RNAi technology, said it has raised $5M in a Series A funding round. According to Arcturus, the funding came from multiple private capital,, high net worth investors from Canada, Japan, and the United States. Names of those capital sources were not announced. READ MORE>>.

Arcturus 153

Arcturus San Diego .Net Venture Capital 153

socalTECH

JUNE 3, 2013

San Diego-based Arcturus Therapeutics , which is developing RNAi therapeutics to treat disease, said this morning that it has raised $1.3M Arcturus Therapeutics is headed by Joseph E. Arcturus Therapeutics is headed by Joseph E. arcturus therapeutics venture capital rnai lifescience biotech' and Canada.

Arcturus 138

Arcturus San Diego .Net Venture Capital 138

Xconomy

JANUARY 3, 2019

As strains of bacteria evolve to fight back against common antibiotics, a slew of biotechnology companies are working to develop ways to combat these “superbugs.” San Diego’s Forge Therapeutics is among those targeting gram-negative bacteria, a type of bacteria that has a protective outer membrane that makes it especially resistant to drugs.

Develop 65

Develop Development San Diego Arcturus 65

Xconomy

APRIL 17, 2020

Alnylam had sold the drug’s development and commercialization rights seven years ago. Late last year Alnylam (NASDAQ: ALNY ) began exploring potential royalty deals for inclisiran, a drug that uses RNA interference to lower cholesterol. Now in the hands of Novartis (NYSE: NVS ), the potential blockbuster seller awaits an FDA decision.

Equity 84

Equity Activity Marketing Company 84

Xconomy

FEBRUARY 9, 2018

A big domino fell this week: data from a two-drug immunotherapy combination developed by Bristol-Myers Squibb. The top biopharma story of the week involves the fast-moving field of lung cancer, which, as we’ve written previously, has several key trials reading out in 2018. But the results, touted as positive, left more questions than answers.

Help 58

Help Develop Development Arcturus 58